BioStem Technologies Joins Nasdaq, Fueling Growth in Allograft Innovation

POMPANO BEACH, FL – August 06, 2026 – In a move signaling a new phase of corporate maturity and ambition, BioStem Technologies, Inc. today announced it has received approval to list its common stock on The Nasdaq Capital Market. The regenerative medicine company, a specialist in perinatal tissue allograft products, will transition from the OTC market and is expected to begin trading on Nasdaq this Friday, August 7, 2026, under its existing ticker symbol, “BSEM.”

This uplisting represents more than a change of venue; it is a strategic milestone that validates the company's recent progress and unlocks critical avenues for future growth. The move is expected to significantly enhance the company's profile among institutional investors, improve trading liquidity for its shareholders, and provide the capital needed to accelerate its mission in a highly competitive field.

"Our uplisting to Nasdaq is an important milestone for BioStem, reflecting the significant progress we have made in strengthening our foundation, streamlining our operations, and executing on our core business strategy," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "We believe this uplisting will expand our access to capital, improve market visibility and liquidity for our shareholders, and reinforce our ability to attract exceptional talent as we continue to grow."

The Strategic Leap from OTC to Nasdaq

For any emerging company, the jump from an over-the-counter (OTC) market to a major national exchange like Nasdaq is a rite of passage. It signifies a departure from the less-regulated, more speculative world of penny stocks into an arena demanding rigorous financial transparency and robust corporate governance. This transition is particularly meaningful in the biotechnology sector, where long development cycles and high research costs make access to stable, long-term capital paramount.

To qualify for the listing, BioStem had to navigate a demanding process, including filing a Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC) to become a fully reporting company. This involved a thorough review of its operations and financial health, including the successful completion of audited financials for the past two fiscal years. Furthermore, the company’s quality management systems have been reviewed and accredited by the American Association of Tissue Banks (AATB), ensuring compliance with both current Good Tissue Practices (cGTP) and current Good Manufacturing Practices (cGMP). These steps are not merely procedural hurdles; they are foundational pillars that build investor confidence.

By meeting Nasdaq’s stringent criteria—which include minimums for stockholders' equity, market value, and share price—BioStem sends a clear signal to the market. "An uplisting is a credibility-builder," noted one industry analyst. "It tells investors that the company has its house in order and is ready for the scrutiny and opportunity that come with playing in the big leagues." This enhanced credibility is crucial for attracting not just capital, but also the top-tier scientific and executive talent needed to innovate and expand.

Fueling Innovation in Regenerative Medicine

At the heart of BioStem's strategy is its focus on advanced allograft solutions derived from perinatal tissue—specifically, amniotic tissues and fluids. These tissues are rich in growth factors and other biological components that are essential for healing and tissue regeneration. The company leverages a suite of proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—designed to preserve the natural, beneficial properties of these tissues for clinical use.

Its product portfolio, which includes brands like VENDAJE®, American Amnion™, and the recently acquired Neox® and Clarix® lines, serves clinicians across a wide range of specialties, particularly in wound care. The global regenerative medicine market is on a steep growth trajectory, with some projections estimating it will reach nearly $170 billion by 2035. The wound care segment, BioStem's primary focus, is among the fastest-growing applications within this market. The Nasdaq listing positions the company to better capitalize on this trend.

With greater access to capital markets, BioStem can more aggressively fund its research and development initiatives, expand its national commercial footprint, and potentially pursue further strategic acquisitions. The January 2026 acquisition of BioTissue’s amniotic membrane-based products, Neox and Clarix, was a transformative step, shifting the company’s primary focus from physician offices to the larger hospital market. This move not only expanded its product portfolio but also provided access to a larger sales force and established group purchasing organization (GPO) contracts. The capital infusion facilitated by the Nasdaq listing will be essential to fully integrate and leverage these new assets.

Navigating a Competitive and Complex Landscape

While the Nasdaq uplisting is a significant victory, BioStem operates in a landscape fraught with challenges. The allograft market is crowded with formidable competitors, including established giants like Medtronic, Stryker, and Johnson & Johnson, all of whom possess vast resources and extensive market reach. To succeed, smaller innovators like BioStem must differentiate themselves through superior science, clinical efficacy, and agile market strategy.

Moreover, the company has faced its own financial headwinds. As recently as late 2025, regulatory filings indicated substantial doubt about its ability to continue as a going concern, a situation precipitated by drastic Medicare reimbursement cuts that slashed pricing on some products by up to 95%. This financial pressure underscores the critical importance of the uplisting. Accessing the public capital markets is not just an opportunity for growth; it's a strategic necessity for shoring up the balance sheet and ensuring long-term viability.

The regenerative medicine field is also subject to intense regulatory scrutiny. The FDA has been cracking down on unproven treatments and misleading marketing claims, making it imperative for companies to back their products with robust clinical data. BioStem’s AATB accreditation and adherence to cGMP standards are vital differentiators in this environment, but the path to broader market acceptance and favorable reimbursement policies requires continuous investment in clinical research.

A New Era of Transparency and Growth

By becoming a Nasdaq-listed entity, BioStem Technologies embraces a new level of accountability. The company will now be subject to Nasdaq's continued listing standards, which mandate maintaining a minimum bid price, timely financial reporting through quarterly and annual SEC filings, and adherence to strict corporate governance rules. This framework, while demanding, provides the transparency that institutional investors and partners require.

The company is already demonstrating momentum. For the first quarter of 2026, BioStem reported revenue of $6.1 million, surpassing its own guidance, and has initiated a full-year 2026 revenue outlook of $25 million to $29 million. This performance, combined with the strategic pivot toward the hospital market, suggests the company’s turnaround strategy is taking hold.

As trading commences on Nasdaq, all eyes will be on BioStem to see how it leverages its newfound status. The upcoming Q2 2026 earnings call, scheduled for August 12, will offer the first opportunity for the leadership team to address its new, broader investor base and outline its plans for the future. For BioStem Technologies, the ringing of the opening bell on Friday will mark the beginning of a crucial new chapter in its journey to advance regenerative medicine.